Subscribe Home Page News Opinion Foreign Policy Politics Policy Legislation Lobbying Hill Life & People Hill Climbers Heard On The Hill Calendar Election 2021 Archives Classifieds
Hill Times Events Inside Ottawa Directory Hill Times Store Hill Times Careers The Wire Report The Lobby Monitor Parliament Now
Reuse & Permissions Advertising FAQ
Contact UsLog In
Policy Briefing: Biotechnology Policy Briefing
The challenges of developing made-in-Canada vaccines may sound daunting, but Canada has done it before. We have a strong track record of innovation and vaccine development, including helping bring the polio vaccine to the world in the 1950s, writes Rob Henderson. Image courtesy of Pixabay

Developing Canada’s vaccine infrastructure for future pandemics will depend on addressing bio-economy labour shortages

Opinion|Rob Henderson
Provided the key players—government, business and academia—work closely together, there’s no reason why we can’t regain our vaccine independence and re-establish our leadership role in vaccine production.
Opinion|Andrew Casey
Amidst concerns related to the emergence of COVID-19 variants and the challenge of vaccinating Canadians and the global population more broadly, whichever party forms the government on Sept. 20 will need to quickly dedicate strategic thinking and resources to the less immediate but equally important imperative of preparing for future pandemic-like events most experts predict will happen.
Canada is simply too small a country to divide our efforts and resources. Indeed, perhaps one of the key benefits of a successful national life sciences strategy will be to secure that alignment of purpose across governments, industry, academia and our research hospitals so that we can move forward in unison, boldly and quickly.
Canada's biotech sector is facing a shortage of labour, with industry stakeholders looking to changes in policies related to immigration and taxes as possible solutions to attract more talent.
Opinion|Trina Racine
While having a strategy to address all aspects of vaccine manufacturing infrastructure is a positive, the key to success will be ensuring the strategy is followed and constantly refined as we progress down the path to biomanufacturing independence.
Opinion|Michael May
To ensure we do not experience the same issues in the future around emerging technology platforms, we need to transition from a pandemic focus and execute on a robust manufacturing strategy that leverages Canadian strengths for meaningful benefit to Canada and measurable global leadership.
Opinion|Chunjiang An
The Government of Canada should develop specialized initiatives to provide the support for further research of biotechnology in oil spill response.

Your group subscription includes premium access to Politics This Morning briefing.